| Case Number | 7571 |
| Request Date | 30/09/2020 |
| Completion Date | 23/02/2021 |
Details of the Request
1. How many patients have been treated with the following drugs (for any disease) in the past 6 months:
- Ampyra (dalfampridine)
- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaferon (interferon beta-1b)
- Brabio (glatiramer acetate)
- Copaxone (glatiramer acetate)
- Extavia (beta interferon-1b)
- Gilenya (fingolimod)
- Lemtrada (alemtuzumab)
- Mavenclad (cladribine)
- Mayzent (siponimod)
- Ocrevus (ocrelizumab)
- Plegridy (peginterferon beta-1a)
- Rebif (beta interferon-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
- Vumerity (diroximel fumarate)
- Zeposia (ozanimod)
2. How many patients have been treated in the past 6 months for the following types of multiple sclerosis:
- Relapsing remitting MS (RRMS)
- Secondary progressive MS (SPMS)
- Primary progressive MS (PPMS)
- Multiple Sclerosis - any type
Details of the Response
How many patients have been treated with the following drugs (for any disease) in the past 6 months:
Data for 6 months to 19/2/21
| Ampyra (dalfampridine) | 0 |
| Aubagio (teriflunomide) | 15 |
| Avonex (interferon beta-1a) | 5 |
| Betaferon (interferon beta-1b) | 0 |
| Brabio (glatiramer acetate) | 25 |
| Copaxone (glatiramer acetate) | 2 |
| Extavia (beta interferon-1b) | 0 |
| Gilenya (fingolimod) | 32 |
| Lemtrada (alemtuzumab) | 0 |
| Mavenclad (cladribine) | 4 |
| Mayzent (siponimod) | 0 |
| Ocrevus (ocrelizumab) | 9 |
| Plegridy (peginterferon beta-1a) | 3 |
| Rebif (beta interferon-1a) | 17 |
| Tecfidera (dimethyl fumarate) | 62 |
| Tysabri (natalizumab) | 22 |
| Vumerity (diroximel fumarate) | 0 |
| Zeposia (ozanimod) | 0 |
2. How many patients have been treated in the past 6 months for the following types of multiple sclerosis:
Data for 6 months to 19/2/21
| Relapsing remitting MS (RRMS) | 204 |
| Secondary progressive MS (SPMS) | 204 |
| Primary progressive MS (PPMS) | 0 |
| Multiple Sclerosis - any type | 0 |



